Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
- MeSH
- chřipka lidská * epidemiologie prevence a kontrola MeSH
- lidé MeSH
- nemocnice MeSH
- primární zdravotní péče MeSH
- roční období MeSH
- studie případů a kontrol MeSH
- vakcinace MeSH
- vakcíny proti chřipce * MeSH
- virus chřipky A, podtyp H1N1 * MeSH
- virus chřipky A, podtyp H3N2 MeSH
- virus chřipky B MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.
- MeSH
- COVID-19 * prevence a kontrola MeSH
- hospitalizace MeSH
- lidé MeSH
- messenger RNA MeSH
- SARS-CoV-2 genetika MeSH
- studie případů a kontrol MeSH
- vakcíny proti COVID-19 * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH